In a 2014 study, tesamorelin reduced both visceral and liver fat after 6 months, and reducing liver fat is important because it helps fix insulin resistance and improves how the body handles glucose.

Scientific Claim

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

Original Statement

“And in 2014, there was a study published in JAMAMA that looked at Tesmearellin's effects on both visceral fat and hpatic fat or liver fat. What they did is uh they gave subjects either 2 millig of tessimarelin or a placebo for 6 months. As you would expect, just like the other study, visceral fat dropped again. But what surprised researchers this time is that liver fat dropped significantly as well. Okay? And that matters because liver fat is one of the strongest drivers of insulin resistance. So think of liver fat like sort of a traffic jam inside your metabolism. When fat accumulates in the liver, glucose handling breaks down, insulin signaling gets sloppy and fat loss everywhere else becomes harder.”

From video:The Most Powerful Peptide for Visceral Belly Fat has Been ReleasedbyThomas DeLauer

Context Details

Domain

pharmacology

Population

human

Subject

tesamorelin

Action

reduces

Target

visceral and hepatic fat, improving insulin sensitivity and glucose metabolism

Intervention Details

Type: drug

Dosage: 2 mg

Duration: 6 months

Evidence from Studies

Supporting (2)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

This study shows that tesamorelin helps reduce belly fat and liver fat in people with HIV who are taking certain medications.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Tesamorelin not only reduces belly fat but also improves liver health in people with HIV.

Contradicting (0)

No contradicting evidence found

Similar Assertions

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

84%

A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

83%

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

83%

In a 12-month randomized, double-blind, placebo-controlled trial, continued tesamorelin treatment led to an 18% reduction in visceral adipose tissue, while discontinuation resulted in rapid fat regain, demonstrating a direct and reversible cause-and-effect relationship.

81%

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.

81%